Abstracts tagged "Drug toxicity"

Abstract Number: 1594 • ACR Convergence 2020
Hydroxychloroquine Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool², Christopher Hansen² and Dorota Lebiedz-Odrobina², ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: One rare but devastating adverse event related to the use of hydroxychloroquine (HCQ) is retinal toxicity. Retinal toxicity rates from HCQ can be as…
Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Zakaria El Ouali¹, Elie Bassa¹, Abdoul-Rahamane Halidou Idrissa¹, Sarah Tazi¹, Samy Housbane², Mohamed Bennani Othmani², Kawtar Nassar¹ and Saadia Janani¹, ¹Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, ²Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…
Abstract Number: 1610 • ACR Convergence 2020
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
Sandeep Surendran¹, Mithun CB¹, Arun Tiwari², Vishal Marwaha¹ and Sekhar Easwar¹, ¹Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, ²Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India
Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
Abstract Number: 0205 • ACR Convergence 2020
Methotrexate Therapy Is Not Associated with an Increased Risk of Liver Fibrosis Assessed by the Fibrosis-4 Index
Jerome Avouac¹, Raphael Degrave², Helene Vergneault¹ and Yannick Allanore¹, ¹Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, Ile-de-France, France
Background/Purpose: Methotrexate (MTX) holds a unique place in the management of rheumatoid arthritis (RA) given its favorable balance between efficacy and safety. However, conflicting data…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 0223 • ACR Convergence 2020
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
Anna Davidson¹, Alize Gunay¹, Ines Colmegna², Diane Lacaille³, Harold Loewen⁴, Michele Meltzer⁵, Yewondwossen Tadese⁶, Zenebe Yirsaw⁶, Sasha Bernatsky⁷ and Carol Hitchon⁴, ¹McGill University, Montreal, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, Canada, ³University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Jefferson University, Philadelphia, PA, ⁶Addis Ababa University, Addis Ababa, Adis Abeba, Ethiopia, ⁷The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Increased awareness of the importance of MTX in rheumatic disease is leading to more MTX use in patients from TB-endemic areas. Current management guidelines…
Abstract Number: 1635 • ACR Convergence 2020
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Amy Kenneally¹, Frédérique Bariguian², Richard Petruschke¹, Arlene Tave³, Jess Edison⁴, Nicholas M. Sicignano⁵ and Francis Barbone¹, ¹GSK Consumer Healthcare, Warren, NJ, ²GSK Consumer Healthcare S.A., Nyon, Switzerland, ³PharmaLex US Corporation, Fairfax, VA, ⁴Walter Reed National Military Medical Center, Bethesda, ⁵Health ResearchTx LLC., Prevose, PA
Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 1779 • ACR Convergence 2020
Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Andras Perl¹, Sundus Mian¹ and Jihad Ben Gabr¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Teratogenic disease-modifying anti-rheumatic disease modifying drugs (DMARDs) are often prescribed to women of childbearing age. Contraception represents an important area of reproductive health for female patients with…
Abstract Number: 0540 • ACR Convergence 2020
Risk of Hydroxychloroquine Retinopathy in the Community
Jesse Dabit¹, Mehmet Hocaoglu², Kevin Moder¹, Andrew Barkmeier³, Wendy Smith³, Thomas O'Byrne¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is used in the treatment of a wide variety of autoimmune diseases. HCQ retinopathy is a feared complication of long-term use. The…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 0588 • ACR Convergence 2020
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Alanna James¹, Kelli Kam¹, Vaneet Sandhu² and Christina Downey³, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].